$2.77
6.73% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US29970R1059
Symbol
EVAX
Sector
Industry

Evaxion Biotech A/S - ADR Stock price

$2.77
+1.16 72.14% 1M
-2.93 51.40% 6M
-1.46 34.47% YTD
-14.18 83.66% 1Y
-7.23 72.30% 5Y
-7.23 72.30% 10Y
-7.23 72.30% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.20 6.73%
ISIN
US29970R1059
Symbol
EVAX
Sector
Industry

Key metrics

Market capitalization $4.17m
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 1.27
Revenue growth (TTM) Revenue growth 2,641.67%
Revenue (TTM) Revenue $3.29m
EBIT (operating result TTM) EBIT $-14.20m
EPS (TTM) EPS $-0.24
P/S forward 1.19
Short interest 1.49%

Is Evaxion Biotech A/S - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Evaxion Biotech A/S - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

Buy
100%

Financial data from Evaxion Biotech A/S - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.29 3.29
2,642% 2,642%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.72 7.72
18% 18%
235%
- Research and Development Expense 9.78 9.78
10% 10%
297%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
30% 30%
-432%
Net Profit -13 -13
9% 9%
-405%

In millions USD.

Don't miss a Thing! We will send you all news about Evaxion Biotech A/S - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evaxion Biotech A/S - ADR Stock News

Neutral
GlobeNewsWire
11 days ago
COPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives funding support from the Gates Foundation to help the world eradicate polio (poliomyelitis) by exploring design options for a new and unique vaccine.
Neutral
Seeking Alpha
18 days ago
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast.
Neutral
GlobeNewsWire
18 days ago
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results.
More Evaxion Biotech A/S - ADR News

Company Profile

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on 11 August, 2008 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Christian Kanstrup
Employees 46
Founded 2008
Website evaxion.ai

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today